Invivyd announces positive LIBERTY Phase 3 topline results for VYD2311
Invivyd (IVVD) reported positive topline results from its LIBERTY Phase 3 study for VYD2311, stating safety and tolerability and that they are superior to mRNA-based COVID-19 vaccines. The company also announced plans for regulatory submissions for VYD2311.